Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective, Multicenter, Open-Label, Randomized, Phase III Clinical Trial of Prevention of Prolonged Air Leak After Lung Resection in High-risk Patients, Applying HEMOPATCH®

NCT02491671 is registered in ClinicalTrials.gov with Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León as lead sponsor.

NCT NCT02491671
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02491671 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective, Multicenter, Open-Label, Randomized, Phase III Clinical Trial of Prevention of Prolonged Air Leak After Lung Resection in High-risk Patients, Applying HEMOPATCH®
Lead sponsor
Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León
Phase
Phase 3
Overall status
Completed
Start date
November 24, 2015
Completion date
June 30, 2019
Enrollment
260 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

lung resection, prolonged air leak